These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 9131500

  • 1. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
    Hansen LM, Batzer FR, Corson SL, Bello S.
    J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
    [Abstract] [Full Text] [Related]

  • 2. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S, Orio F, Russo T, Falbo A, Cascella T, Doldo P, Nappi C, Lombardi G, Mastrantonio P, Zullo F.
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [Abstract] [Full Text] [Related]

  • 3. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG, Vercellini P, Meschìa M, Oldani S, Bramante T.
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
    Cramer SF.
    Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
    Saltiel E.
    Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243
    [Abstract] [Full Text] [Related]

  • 8. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
    Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N.
    J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
    [Abstract] [Full Text] [Related]

  • 9. Changes in insulin sensitivity during GnRH agonist treatment in premenopausal women with leiomyoma.
    Matsui S, Yasui T, Tani A, Kunimi K, Uemura H, Yamamoto S, Kuwahara A, Matsuzaki T, Tsuchiya N, Yuzurihara M, Kase Y, Irahara M.
    Clin Chim Acta; 2012 Jun 14; 413(11-12):960-5. PubMed ID: 22366120
    [Abstract] [Full Text] [Related]

  • 10. Regulation of dosage of conjugated equine estrogen is useful for add-back therapy.
    Hoshimoto K, Hayashi M, Ohkura T.
    J Med; 2000 Jun 14; 31(3-4):167-75. PubMed ID: 11280448
    [Abstract] [Full Text] [Related]

  • 11. Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy.
    Warnock JK, Bundren JC.
    Psychopharmacol Bull; 1997 Jun 14; 33(2):311-6. PubMed ID: 9230649
    [Abstract] [Full Text] [Related]

  • 12. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
    Mizutani T, Sugihara A, Honma H, Komura H, Nakamuro K, Terada N.
    Gynecol Endocrinol; 2005 Feb 14; 20(2):80-3. PubMed ID: 15823826
    [Abstract] [Full Text] [Related]

  • 13. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K, Kawamura N, Ishiko O, Ogita S.
    Int J Oncol; 2002 Feb 14; 20(2):279-83. PubMed ID: 11788889
    [Abstract] [Full Text] [Related]

  • 14. Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol?
    Muneyyirci-Delale O, Weisberg GW.
    Int J Fertil Womens Med; 2000 Feb 14; 45(6):368-71. PubMed ID: 11140546
    [Abstract] [Full Text] [Related]

  • 15. Short term treatment with leuprolide acetate is a successful adjunct to surgical therapy of leiomyomas of the uterus.
    Coddington CC, Brzyski R, Hansen KA, Corley DR, McIntyre-Seltman K, Jones HW.
    Surg Gynecol Obstet; 1992 Jul 14; 175(1):57-63. PubMed ID: 1621201
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
    Stolz W, Pfützenreuter N.
    Zentralbl Gynakol; 1997 Jul 14; 119(10):468-75. PubMed ID: 9432825
    [Abstract] [Full Text] [Related]

  • 17. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
    Mizutani T, Sugihara A, Nakamuro K, Terada N.
    J Clin Endocrinol Metab; 1998 Apr 14; 83(4):1253-5. PubMed ID: 9543151
    [Abstract] [Full Text] [Related]

  • 18. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
    Palomba S, Orio F, Falbo A, Oppedisano R, Tolino A, Zullo F.
    Fertil Steril; 2008 Jul 14; 90(1):165-73. PubMed ID: 18001721
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
    Ichigo S, Takagi H, Matsunami K, Suzuki N, Imai A.
    Arch Gynecol Obstet; 2011 Sep 14; 284(3):667-70. PubMed ID: 21052701
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.